Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-CoV-2 infection?
Identifieur interne : 000F15 ( Main/Corpus ); précédent : 000F14; suivant : 000F16Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-CoV-2 infection?
Auteurs : Sudhir Mehta ; Sudhir Bhandari ; Shaurya MehtaSource :
- Journal of global antimicrobial resistance [ 2213-7173 ] ; 2020.
English descriptors
- KwdEn :
- Antiviral Agents (administration & dosage), Betacoronavirus (isolation & purification), COVID-19 (MeSH), Coronavirus Infections (drug therapy), Coronavirus Infections (prevention & control), Coronavirus Infections (virology), Health Personnel (MeSH), Humans (MeSH), Hydroxychloroquine (administration & dosage), India (MeSH), Pandemics (prevention & control), Pneumonia, Viral (prevention & control), Pneumonia, Viral (virology), Pre-Exposure Prophylaxis (methods), SARS-CoV-2 (MeSH).
- MESH :
- chemical , administration & dosage : Antiviral Agents, Hydroxychloroquine.
- geographic : India.
- drug therapy : Coronavirus Infections.
- isolation & purification : Betacoronavirus.
- methods : Pre-Exposure Prophylaxis.
- prevention & control : Coronavirus Infections, Pandemics, Pneumonia, Viral.
- virology : Coronavirus Infections, Pneumonia, Viral.
- COVID-19, Health Personnel, Humans, SARS-CoV-2.
Abstract
The potentiality of Hydroxychloroquine (HCQ) for pre-exposure prophylaxis against SARS-CoV-2 has not been explored in randomized controlled trials. However, there is rationale behind this potentiality in terms of demonstrated in-vitro effect of HCQ against SARS-CoV-2, safety profile of HCQ in healthy individuals and a recent observational study demonstrating benefits of HCQ prophylaxis in terms of a significant reduction (>80%) in the odds of SARS-CoV-2 infection in the health-care workers (HCWs) with the intake of six or more doses of HCQ prophylaxis as per the guidelines of the National Task Force for COVID-19 in India. Hence, pre-exposure prophylaxis with HCQ in appears to be a reasonable strategy in the current scenario for prevention of SARS-CoV-2 infection in healthy HCWs.
DOI: 10.1016/j.jgar.2020.07.022
PubMed: 32777441
PubMed Central: PMC7836824
Links to Exploration step
pubmed:32777441Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-CoV-2 infection?</title>
<author><name sortKey="Mehta, Sudhir" sort="Mehta, Sudhir" uniqKey="Mehta S" first="Sudhir" last="Mehta">Sudhir Mehta</name>
<affiliation><nlm:affiliation>Department of Medicine, SMS Medical College, Jaipur, India. Electronic address: s.smehta@hotmail.com.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Bhandari, Sudhir" sort="Bhandari, Sudhir" uniqKey="Bhandari S" first="Sudhir" last="Bhandari">Sudhir Bhandari</name>
<affiliation><nlm:affiliation>Department of Medicine, SMS Medical College, Jaipur, India.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Mehta, Shaurya" sort="Mehta, Shaurya" uniqKey="Mehta S" first="Shaurya" last="Mehta">Shaurya Mehta</name>
<affiliation><nlm:affiliation>Jaslok Hospital & Research Centre, Mumbai, India.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32777441</idno>
<idno type="pmid">32777441</idno>
<idno type="doi">10.1016/j.jgar.2020.07.022</idno>
<idno type="pmc">PMC7836824</idno>
<idno type="wicri:Area/Main/Corpus">000F15</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000F15</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-CoV-2 infection?</title>
<author><name sortKey="Mehta, Sudhir" sort="Mehta, Sudhir" uniqKey="Mehta S" first="Sudhir" last="Mehta">Sudhir Mehta</name>
<affiliation><nlm:affiliation>Department of Medicine, SMS Medical College, Jaipur, India. Electronic address: s.smehta@hotmail.com.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Bhandari, Sudhir" sort="Bhandari, Sudhir" uniqKey="Bhandari S" first="Sudhir" last="Bhandari">Sudhir Bhandari</name>
<affiliation><nlm:affiliation>Department of Medicine, SMS Medical College, Jaipur, India.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Mehta, Shaurya" sort="Mehta, Shaurya" uniqKey="Mehta S" first="Shaurya" last="Mehta">Shaurya Mehta</name>
<affiliation><nlm:affiliation>Jaslok Hospital & Research Centre, Mumbai, India.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of global antimicrobial resistance</title>
<idno type="eISSN">2213-7173</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (administration & dosage)</term>
<term>Betacoronavirus (isolation & purification)</term>
<term>COVID-19 (MeSH)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Coronavirus Infections (prevention & control)</term>
<term>Coronavirus Infections (virology)</term>
<term>Health Personnel (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (administration & dosage)</term>
<term>India (MeSH)</term>
<term>Pandemics (prevention & control)</term>
<term>Pneumonia, Viral (prevention & control)</term>
<term>Pneumonia, Viral (virology)</term>
<term>Pre-Exposure Prophylaxis (methods)</term>
<term>SARS-CoV-2 (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiviral Agents</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>India</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Pre-Exposure Prophylaxis</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pandemics</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>COVID-19</term>
<term>Health Personnel</term>
<term>Humans</term>
<term>SARS-CoV-2</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The potentiality of Hydroxychloroquine (HCQ) for pre-exposure prophylaxis against SARS-CoV-2 has not been explored in randomized controlled trials. However, there is rationale behind this potentiality in terms of demonstrated in-vitro effect of HCQ against SARS-CoV-2, safety profile of HCQ in healthy individuals and a recent observational study demonstrating benefits of HCQ prophylaxis in terms of a significant reduction (>80%) in the odds of SARS-CoV-2 infection in the health-care workers (HCWs) with the intake of six or more doses of HCQ prophylaxis as per the guidelines of the National Task Force for COVID-19 in India. Hence, pre-exposure prophylaxis with HCQ in appears to be a reasonable strategy in the current scenario for prevention of SARS-CoV-2 infection in healthy HCWs.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32777441</PMID>
<DateCompleted><Year>2020</Year>
<Month>10</Month>
<Day>19</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>01</Month>
<Day>29</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2213-7173</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>22</Volume>
<PubDate><Year>2020</Year>
<Month>09</Month>
</PubDate>
</JournalIssue>
<Title>Journal of global antimicrobial resistance</Title>
<ISOAbbreviation>J Glob Antimicrob Resist</ISOAbbreviation>
</Journal>
<ArticleTitle>Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-CoV-2 infection?</ArticleTitle>
<Pagination><MedlinePgn>864-865</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S2213-7165(20)30194-6</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jgar.2020.07.022</ELocationID>
<Abstract><AbstractText>The potentiality of Hydroxychloroquine (HCQ) for pre-exposure prophylaxis against SARS-CoV-2 has not been explored in randomized controlled trials. However, there is rationale behind this potentiality in terms of demonstrated in-vitro effect of HCQ against SARS-CoV-2, safety profile of HCQ in healthy individuals and a recent observational study demonstrating benefits of HCQ prophylaxis in terms of a significant reduction (>80%) in the odds of SARS-CoV-2 infection in the health-care workers (HCWs) with the intake of six or more doses of HCQ prophylaxis as per the guidelines of the National Task Force for COVID-19 in India. Hence, pre-exposure prophylaxis with HCQ in appears to be a reasonable strategy in the current scenario for prevention of SARS-CoV-2 infection in healthy HCWs.</AbstractText>
<CopyrightInformation>Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mehta</LastName>
<ForeName>Sudhir</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, SMS Medical College, Jaipur, India. Electronic address: s.smehta@hotmail.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bhandari</LastName>
<ForeName>Sudhir</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, SMS Medical College, Jaipur, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mehta</LastName>
<ForeName>Shaurya</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Jaslok Hospital & Research Centre, Mumbai, India.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>08</Month>
<Day>07</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>J Glob Antimicrob Resist</MedlineTA>
<NlmUniqueID>101622459</NlmUniqueID>
<ISSNLinking>2213-7165</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
<QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006282" MajorTopicYN="N">Health Personnel</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007194" MajorTopicYN="N" Type="Geographic">India</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D065129" MajorTopicYN="N">Pre-Exposure Prophylaxis</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>06</Month>
<Day>24</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>07</Month>
<Day>14</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>07</Month>
<Day>24</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>8</Month>
<Day>11</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>10</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>8</Month>
<Day>11</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32777441</ArticleId>
<ArticleId IdType="pii">S2213-7165(20)30194-6</ArticleId>
<ArticleId IdType="doi">10.1016/j.jgar.2020.07.022</ArticleId>
<ArticleId IdType="pmc">PMC7836824</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):732-739</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 May;55(5):105938</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32171740</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Aug 6;383(6):517-525</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32492293</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Med. 2018 Nov 7;16(1):200</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30400791</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 May 22;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32450107</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Indian J Med Res. 2020 May;151(5):459-467</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32611916</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Discov. 2020 Mar 18;6:16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32194981</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F15 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000F15 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= CovidChloroV1 |flux= Main |étape= Corpus |type= RBID |clé= pubmed:32777441 |texte= Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-CoV-2 infection? }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32777441" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a CovidChloroV1
![]() | This area was generated with Dilib version V0.6.38. | ![]() |